Elevance Health $ELV stock confirmed a MACD buy signal on November 30, 2022. The stock is in a technical uptrend and is trading within an uptrend channel.
Dark Pool Trading In Elevance Health $ELV Stock
Dark pool trading occurred in Elevance Health $ELV stock on November 25, and November 29, 2022. The unusually large dark pool trades were valued at $81 million and $57 million, respectively. We think the dark pool trades were buy orders because $ELV stock rose following the prints hitting the tape.
Twenty-one Elevance Health Medicaid Plans Receive NCQA Health Equity Accreditation
Elevance Health made the announcement that 21 of its affiliated Medicaid plans were the first in the country to receive a full three-year accreditation for health equity from the National Committee for Quality Assurance on November 28, 2022. Elevance Health’s dedication to advancing health equity and giving the needs of entire communities of people who have historically been marginalized in both the economic and social spheres of society the highest priority is evident in the accreditation.
“Advancing health equity is a priority for everyone at Elevance Health, and we hold ourselves accountable for addressing the root causes that drive poor health outcomes,” said Aimée Dailey, President of Medicaid at Elevance Health. “Ninety-three percent of our Medicaid members are now served by a health plan that has earned this health equity accreditation, a scale unmatched in the industry. It’s an opportunity to continue to address the unique needs and improve the health of the diverse communities we serve.”
Elevance Health to acquire BioPlus, terms undisclosed
On November 9, 2022, Elevance Health revealed that it had reached an agreement to purchase BioPlus, a comprehensive specialty pharmacy, from CarepathRx, a Nautic Partners portfolio company. For patients with complex and chronic conditions like cancer, multiple sclerosis, hepatitis C, autoimmune diseases, and rheumatology, BioPlus offers a full range of specialty pharmacy services. With the support of integrated programs across Elevance Health and Carelon, this acquisition will help Elevance Health meet the specialty drug needs of its clients and customers in a whole-health approach. The transaction is expected to close in the first half of 2023, subject to customary closing conditions. The impact of BioPlus on adjusted earnings per share in 2023 is not anticipated to be significant.